Ensign Peak Advisors
ACAD icon

Ensign Peak Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Ensign Peak Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$204K Buy
8,050
+150
+2% +$3.3K ﹤0.01% 1368
2026
Q1 		$176K Hold
7,900
– – ﹤0.01% 1369
2025
Q4 		$211K Sell
7,900
-16,000
-67% -$382K ﹤0.01% 1296
2025
Q3 		$510K Sell
23,900
-17,800
-43% -$421K ﹤0.01% 1377
2025
Q2 		$899K Sell
41,700
-18,750
-31% -$349K ﹤0.01% 1302
2025
Q1 		$1M Hold
60,450
– – ﹤0.01% 1243
2024
Q4 		$1.11M Hold
60,450
– – ﹤0.01% 1256
2024
Q3 		$930K Hold
60,450
– – ﹤0.01% 1364
2024
Q2 		$982K Hold
60,450
– – ﹤0.01% 1288
2024
Q1 		$1.12M Sell
60,450
-3,050
-5% -$75.6K ﹤0.01% 1242
2023
Q4 		$1.99M Hold
63,500
– – ﹤0.01% 917
2023
Q3 		$1.32M Hold
63,500
– – ﹤0.01% 1002
2023
Q2 		$1.52M Hold
63,500
– – ﹤0.01% 979
2023
Q1 		$1.2M Hold
63,500
– – ﹤0.01% 1096
2022
Q4 		$1.01M Buy
63,500
+23,500
+59% +$367K ﹤0.01% 1154
2022
Q3 		$654K Sell
40,000
-101,470
-72% -$1.64M ﹤0.01% 1320
2022
Q2 		$1.99M Buy
141,470
+101,470
+254% +$1.89M ﹤0.01% 803
2022
Q1 		$969K Buy
40,000
+10,220
+34% +$247K ﹤0.01% 1226
2021
Q4 		$695K Buy
+29,780
New +$599K ﹤0.01% 1469
2021
Q2 		– Sell
-59,702
Closed -$1.54M – 1823
2021
Q1 		$1.54M Sell
59,702
-61,137
-51% -$2.69M ﹤0.01% 1233
2020
Q4 		$6.46M Sell
120,839
-5,439
-4% -$270K 0.01% 527
2020
Q3 		$5.21M Buy
126,278
+109,515
+653% +$4.73M 0.01% 618
2020
Q2 		$813K Buy
16,763
+2,470
+17% +$119K ﹤0.01% 1340
2020
Q1 		$604K Buy
+14,293
New +$589K ﹤0.01% 1342

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors's ACAD Position: Q2 2026 in Review

Ensign Peak Advisors increased its Acadia Pharmaceuticals (ACAD) stake by 1.9% in Q2 2026, buying an estimated $3.3K and bringing the position to 8,050 shares worth $204K. The position accounts for ﹤0.01% of the portfolio, ranked #1368.

Ensign Peak Advisors first reported a position in ACAD in Q1 2020 and has held it in 24 quarters since. The position peaked at $6.46M in Q4 2020. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Ensign Peak Advisors held 8,050 shares of Acadia Pharmaceuticals worth $204K as of Q2 2026.
  • Ensign Peak Advisors bought 150 Acadia Pharmaceuticals shares in Q2 2026, an estimated $3.3K.
  • Acadia Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1368 holding.
  • Ensign Peak Advisors first reported a position in Acadia Pharmaceuticals in Q1 2020 and has held it in 24 quarters since.
  • Ensign Peak Advisors's Acadia Pharmaceuticals position peaked at $6.46M in Q4 2020.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.